Conferences - Results from #720

Viewing 721-740 of 11869 articles

AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: The Next Generation Trial: Assessing 18F-PSMA-1007 PET and MRI in Primary Staging of Prostate Cancer Patients

AUA 2024: Replacing ReTUR with Cystoscopy in High-Grade T1 NMIBC Patients: Confirmatory Results from the HuNIRe Trial

AUA 2024: N-803 plus BCG Complete Response Rate in NMIBC CIS: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032)

AUA 2024: Rates and Predictors of False Node-Positive PSMA-PET in Patients Treated with Radical Prostatectomy and Extend Pelvic Lymph-Node Dissection: Results From a Large, Multi-Institutional Database

AUA 2024: AUA Guidelines: Salvage Therapy for Prostate Cancer

AUA 2024: Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

AUA 2024: A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients with Microhematuria: The STRATA: Safe Testing of Risk for Asymptomatic Microhematuria Trial

AUA 2024: Challenging the Paradigm of "BCG Unresponsive" Bladder Cancer: Does Additional BCG Have an Effect?

AUA 2024: Effects of Neoadjuvant Chemotherapy on Rates of Depression in Muscle Invasive Bladder Cancer

AUA 2024: The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts the Need for Intervention for Patients on Active Surveillance

AUA 2024: Phase I Dose-Escalation Trial of Multiple and Fractionated-Dose PSMA-Targeted Alpha Radionuclide (225Ac-J591) for Metastatic Castration-Resistant Prostate Cancer

AUA 2024: Smoking Status is Associated with Poor Mental Health in Bladder Cancer Patients and Survivors

AUA 2024: Quality of Treatment with Targeted Therapies for Advanced Prostate Cancer by Specialist: Do Patients Who Are Managed by Urologists Fare Differently?

AUA 2024: Differences in Barriers and Facilitators to First-Line Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer Between Urologists and Oncologists: A Sub-Analysis of the IMPLEMENT Study

AUA 2024: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

AUA 2024: Prostate-Specific Antigen Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

AUA 2024: Analyzing the Percentage of Positive 68Ga-PSMA-PET/CT Scans Based on PSA Ranges Across Distinct Indications for the Scan

AUA 2024: SOPHIA Study: The New Artificial Urinary Sphincter UroActive™: Results of the First in Man Study at 6 Months Post-Activation

AUA 2024: State-of-the-Art Lecture: Prostate Cancer Screening in High-risk Groups

32
33
34
35
36
37
38
39
40
41